Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Jacob, Francis ^a,b   Ukegjini, Kristjan ^a   Nixdorf, Sheri ^b   Ford, Caroline E ^b   Olivier, Jake ^b   Caduff, Rosmarie ^a   Scurry, James P ^c   Guertler, Rea ^b   Hornung, Daniela ^d   Mueller, Renato ^e   Fink, Daniel A ^f   Hacker, Neville F ^g   Heinzelmann Schwarz, Viola A ^a,b,g  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

^g ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SECRETED FRIZZLED RELATED PROTEIN 4; WNT PROTEIN; ONCOPROTEIN; SFRP4 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOSS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MALIGNANT TRANSFORMATION; ONCOGENE; OUTCOME ASSESSMENT; OVARY CANCER; PHENOTYPE; PREDICTIVE VALUE; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SFRP4 GENE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ASCITES; BLOOD; CANCER INVASION; CELL MEMBRANE; CELL TRANSFORMATION; COHORT ANALYSIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL LINE;

ASCITES; CELL LINE, TUMOR; CELL MEMBRANE; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84857402982     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031885     Document Type: Article

References (46)

1. Russell W, (2002) Adenovirus gene therapy for ovarian cancer. J Natl Cancer Inst 94: 706-707.
2. Bast RC Jr, Pusztai L, Kerns BJ, MacDonald JA, Jordan P, et al. (1998) Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma 17: 313-321.
3. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, et al. (2004) Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 10: 4427-4436.
4. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, et al. (2006) A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 94: 904-913.
5. Agarwal R, Linch M, Kaye SB, (2006) Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 32: 875-886.
6. Crijns AP, Gerbens F, Plantinga AE, Meersma GJ, de Jong S, et al. (2006) A biological question and a balanced (orthogonal) design: the ingredients to efficiently analyze two-color microarrays with Confirmatory Factor Analysis. BMC Genomics 7: 232.
7. Nusse R, Varmus H, (1992) Wnt Genes. Cell 69: 1073-1087.
8. Polakis P, (2000) Wnt signaling and cancer. Genes Dev 14: 1837-1851.
9. Dejmek J, Dejmek A, Safholm A, Sjolander A, Andersson T, (2005) Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 65: 9142-9146.
10. Dejmek J, Leandersson K, Manjer J, Bjartell A, Emdin SO, et al. (2005) Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res 11: 520-528.
11. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, et al. (2002) Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1: 279-288.
12. Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, et al. (2011) Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 17: 4052-4062.
13. Huang Y, Liu G, Zhang B, Xu G, Xiong W, et al. (2010) Wnt-5a regulates proliferation in lung cancer cells. Oncol Rep 23: 177-181.
14. Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, et al. (2002) Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 21: 4060-4064.
15. Katoh M, (2005) WNT/PCP signaling pathway and human cancer (review). Oncol Rep 14: 1583-1588.
16. Kohn AD, Moon RT, (2005) Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium 38: 439-446.
17. Moon RT, Kohn AD, De Ferrari GV, Kaykas A, (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701.
18. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, et al. (2003) Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 162: 899-908.
19. Wu R, Zhai Y, Fearon ER, Cho KR, (2001) Diverse mechanisms of b-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Research 61: 8247-8255.
20. Schwartz DR, Wu R, Kardia SL, Levin AM, Huang CC, et al. (2003) Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 63: 2913-2922.
21. Miller J, (2001) The Wnts. Genome Biology 3 (1): 1-15.
22. Zhai Y, Wu R, Schwartz DR, Darrah D, Reed H, et al. (2002) Role of b-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. American Journal of Pathology 160: 1229-1238.
23. Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, et al. (2004) Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10: 5168-5177.
24. Janssens N, Andries L, Janicot M, Perera T, Bakker A, (2004) Alteration of frizzled expression in renal cell carcinoma. Tumour Biol 25: 161-171.
25. Lin K, Wang S, Julius MA, Kitajewski J, Moos M Jr, et al. (1997) The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation of Wnt signaling. Proc Natl Acad Sci U S A 94: 11196-11200.
26. Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, et al. (1999) Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J Biol Chem 274: 16180-16187.
27. Shi Y, He B, You L, Jablons DM, (2007) Roles of secreted frizzled-related proteins in cancer. Acta Pharmacol Sin 28: 1499-1504.
28. Takada T, Yagi Y, Maekita T, Imura M, Nakagawa S, et al. (2004) Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci 95: 741-744.
29. Su HY, Lai HC, Lin YW, Chou YC, Liu CY, et al. (2009) An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer 124: 387-393.
30. Li YL, Ye F, Hu Y, Lu WG, Xie X, (2009) Identification of suitable reference genes for gene expression studies of human serous ovarian cancer by real-time polymerase chain reaction. Anal Biochem 394: 110-116.
31. Liu H, Lang J, Zhou Q, Shan D, Li Q, (2007) Detection of endometriosis with the use of plasma protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Fertil Steril 87: 988-990.
32. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
33. Arvidsson S, Kwasniewski M, Riano-Pachon DM, Mueller-Roeber B, (2008) QuantPrime-a flexible tool for reliable high-throughput primer design for quantitative PCR. BMC Bioinformatics 9: 465.
34. Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, et al. (2011) No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 121: 487-491.
35. Carmon KS, Loose DS, (2008) Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells. Mol Cancer Res 6: 1017-1028.
36. Risinger JI, Maxwell GL, Chandramouli GV, Aprelikova O, Litzi T, et al. (2005) Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling. Cancer Res 65: 5031-5037.
37. Horvath LG, Henshall SM, Kench JG, Saunders DN, Lee CS, et al. (2004) Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro. Clin Cancer Res 10: 615-625.
38. Drake J, Shearwood AM, White J, Friis R, Zeps N, et al. (2009) Expression of secreted frizzled-related protein 4 (SFRP4) in primary serous ovarian tumours. Eur J Gynaecol Oncol 30: 133-141.
39. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, et al. (2003) WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201: 204-212.
40. Wong SCC, Lo SFE, Lee KC, Yam JWP, Chan JKC, et al. (2002) Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. Journal of Pathology 196: 145-153.
41. Kurman RJ, Shih Ie M, (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34: 433-443.
42. Horvath LG, Henshall SM, Lee CS, Kench JG, Golovsky D, et al. (2005) Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer 113: 415-422.
43. Horvath LG, Lelliott JE, Kench JG, Lee CS, Williams ED, et al. (2007) Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. Prostate 67: 1081-1090.
44. He QY, Zhou Y, Wong E, Ehlen TG, Auersperg N, et al. (2005) Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies. Gynecol Oncol 98: 68-76.
45. Jonsson M, Dejmek J, Bendahl PO, Andersson T, (2002) Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 62: 409-416.
46. Ford CE, Ekstrom EJ, Andersson T, (2009) Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells. Proc Natl Acad Sci U S A 106: 3919-3924.